Satellos Bioscience (MSLE) Change in Receivables (2025 - 2026)

Satellos Bioscience (MSLE) posted quarterly Change in Receivables of $726000.0 for Q1 2026, up 96.22% quarter-over-quarter from $370000.0 in Q4 2025.

Satellos Bioscience (MSLE) Change in Receivables (2025 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has reported Change in Receivables for 2 consecutive years, with $726000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Change in Receivables changed N/A year-over-year to $726000.0; the TTM figure through Mar 2026 stood at $726000.0 (changed N/A YoY), while the FY2025 annual figure was $370000.0, up 1256.25% from the prior year.
Change in Receivables grew to $726000.0 in Q1 2026 per MSLE's latest filing, from $370000.0 in the prior quarter.
Across five years, Change in Receivables topped out at $726000.0 in Q1 2026 and bottomed at $370000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	-
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	-
10	Satellos Bioscience	206.54 Mn	206.54 Mn	-	783,000.00

Download Data